Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Bristol-Myers Squibb Wins FDA Approval for Opdivo-Yervoy Combo in First-Line HCC Treatment

Fineline Cube Apr 14, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval from the US Food and...

Company Deals

Jiangxi Institute of Biological Products Files for Hong Kong IPO Amid Strong Market Position

Fineline Cube Apr 14, 2025

Jiangxi Institute of Biological Products Inc., China’s largest provider and exporter of human tetanus antitoxin...

Company Deals Drug

Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment

Fineline Cube Apr 14, 2025

Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled...

Company Drug

CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of SYH2046 in Heart Failure

Fineline Cube Apr 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Amgen’s Imdelltra Shows Positive Phase III Results in Small Cell Lung Cancer

Fineline Cube Apr 14, 2025

US biotech giant Amgen (NASDAQ: AMGN) has announced positive results from the global Phase III...

Company Medical Device

Shanghai Microport EP Medtech Secures NMPA Fast-Track Designation for EasyEcho Catheter

Fineline Cube Apr 14, 2025

China’s Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) has announced that it has received...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-3792 and HRS-9190

Fineline Cube Apr 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received separate...

Company Drug

Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer

Fineline Cube Apr 14, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...

Company Drug

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma

Fineline Cube Apr 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received approval from...

Company Drug

CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin

Fineline Cube Apr 14, 2025

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received...

Company

Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs

Fineline Cube Apr 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...

Company Drug

Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA

Fineline Cube Apr 11, 2025

Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...

Company Drug

Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy

Fineline Cube Apr 11, 2025

China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...

Company Drug

Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP

Fineline Cube Apr 11, 2025

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...

Company Deals

Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology

Fineline Cube Apr 11, 2025

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...

Company Deals Medical Device

INTCO Medical and JD Healthcare Partner to Innovate ‘Internet + Healthcare’ Service Models

Fineline Cube Apr 11, 2025

China-based INTCO Medical (SHE: 300677), a high-tech manufacturer of medical consumables and equipment, has entered...

Company Medical Device

KingstronBio’s Prostyle A Valve Gains NMPA Approval, Setting New Benchmark in Transcatheter Aortic Valve Replacement

Fineline Cube Apr 11, 2025

KingstronBio, a Changshu-based structural heart disease device manufacturer, has obtained marketing approval from China’s National...

Company Deals

iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology

Fineline Cube Apr 11, 2025

Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...

Company

Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs

Fineline Cube Apr 11, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...

Company Drug

Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment

Fineline Cube Apr 11, 2025

China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...

Posts pagination

1 … 173 174 175 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.